Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Depot Lupron + estrogen is an experimental combination regimen consisting of leuprolide acetate (brand name: Lupron Depot) and supplemental estrogen. Leuprolide is a synthetic gonadotropin-releasing hormone (GnRH) agonist that, when administered in a depot formulation, induces a state of medical oophorectomy by suppressing the pituitary-gonadal axis and reducing endogenous production of estrogen, progesterone, and androgens. In clinical research conducted by the University of Chicago, this regimen is used to investigate the metabolic and hormonal drivers of obstructive sleep apnea (OSA) in women with polycystic ovary syndrome (PCOS). By suppressing endogenous hormones and selectively adding back estrogen or progesterone, researchers can isolate the specific effects of hyperandrogenemia and hormonal dysregulation on sleep-disordered breathing and insulin resistance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on leuprolide + estrogen.